Cardima
This article was originally published in The Gray Sheet
Executive Summary
Firm says it will need to raise additional capital to continue developing and marketing its products following a Nasdaq delisting warning in early April. The company's products include the Revelation Tx microcatheter-based system for treating atrial fibrillation. Firm is set to appeal the Nasdaq decision